REG - Oxford Biomedica PLC - Director Dealings / Market Share Sale and Purchase

Oxford BioMedicaAnnouncement

10/08/2018 11:40

RNS Number : 4911X
Oxford Biomedica PLC
10 August 2018
 


 
 
 
 
 
 
Director Dealings / Market Share Sale and Purchase
 
Oxford, UK - 10 August 2018: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), a leading gene and cell therapy group, was informed that on 07 August 2018 John Dawson, Chief Executive Officer, exercised options over 20,000 ordinary shares of 50p each ("Ordinary Shares") in the Company.  The options were exercisable at a cost of 50p per share and Mr Dawson has sold 10,046 shares at 890.1p in order to fund the £89,420 cost of exercise. These options were granted in October 2008, under the Company's 2007 Long Term Incentive Plan, and which were due to expire. 
 
Following the exercise Mr Dawson holds 88,468 ordinary shares of 50p each ("Ordinary Shares") in the Company, 0.13% of the Company's issued share capital.
 
The issued share capital of the Company is 65,752,788 ordinary shares of 50 pence each.
The Notification of Dealing Forms set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.
 
Notification of Dealing Form
 



1.


Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")




a)


Name


John Dawson




2.


Reason for the notification




a)


Position/status


Chief Executive Officer
 




b)


Initial notification/
amendment


Initial Notification




3.


Details of the Issuer




a)


Name


Oxford BioMedica plc




b)


LEI code


213800S1GVQNXQ15K851




4.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a)


Description of the financial instrument
 
Identification code


Ordinary Shares of 50 pence each
 
ISIN: GB00BDFBVT43




b)


Nature of the transaction


Exercise of options




c)


Currency


GBP - British pound




d)


Price(s) and volumes(s)


 



Price(s)


Volume(s)




£0.50


20,000



 
 




e)


Aggregated information
-   Aggregate volume
 
-   Price
 
-   Aggregated total
 


 
20,000
 
 
£0.50
 
£10,000.00




f)


Date of the transaction


2018-08-07




g)


Place of the transaction


London Stock Exchange, Main Market (XLON)



 
 



1.


Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")




a)


Name


John Dawson




2.


Reason for the notification




a)


Position/status


Chief Executive Officer
 




b)


Initial notification/
amendment


Initial Notification




3.


Details of the Issuer




a)


Name


Oxford BioMedica plc




b)


LEI code


213800S1GVQNXQ15K851




4.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a)


Description of the financial instrument
 
Identification code


Ordinary Shares of 50 pence each
 
ISIN: GB00BDFBVT43




b)


Nature of the transaction


Disposal




c)


Currency


GBP - British pound




d)


Price(s) and volumes(s)


 



Price(s)


Volume(s)




£8.901093


10,046



 
 




e)


Aggregated information
-   Aggregate volume
 
-   Price
 
-   Aggregated total
 


 
10,046
 
 
£8.901
 
£89,420.38




f)


Date of the transaction


2018-08-07




g)


Place of the transaction


London Stock Exchange, Main Market (XLON)



 
-Ends-
 



For further information, please contact:


 




 
Oxford BioMedica plc:
John Dawson,  Chief Executive Officer
Stuart Paynter, Chief Financial Officer


 
Tel: +44 (0)1865 783 000




 
Financial and corporate communications enquiries:
Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal/Olivia Manser/Laura Thornton
 


 
Tel: +44 (0)20 3709 5700



 
Notes for editors
 
About Oxford BioMedica®
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Bioverativ, Sanofi, Axovant, Orchard Therapeutics, GC LabCell and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 320 people. Further information is available at www.oxfordbiomedica.co.uk
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHPMMMTMBJBBAP